Embrace Moving Goalposts

A large proportion of [our] performance in 2007 came from the lessons
learnt from mistakes in 2003 and 2004. Think of it as a return on prior
year losses.” (Nick Sleep)

Back in 2016, I had an “aha moment” while exchanging a couple of emails with the editor of an investment newsletter built around the dividend yield theory. The idea was that reliable dividend-paying stocks tend to offer great value when they hit such a low price that their dividend yield reaches extremely high levels. While this may only hold for a group of select blue chips, the service promised to identify those and reveal the dividend yield levels where they presented historically attractive buying opportunities. This sounded like the Holy Grail of investing! The concept suggested that you can play the investment game with fixed goalposts, such as buying McDonald’s when it offers a 3.6% dividend yield and selling it when the price rises so much that the yield drops to 2.1%, signaling overvaluation. Easy-peasy, except that it doesn’t work like this.

For example, I bought a restaurant stock that was supposed to be on sale with an entry dividend yield of 3.20%. Over time, that undervalued yield threshold published in the newsletter was moved to 3.75%, implying that I might have overpaid by ~15%. This prompted my questions: Are we trying to shoot accurately with the goalposts moving? What are the underlying reasons that can change these yield thresholds? Armed with decades of experience, the editor answered that both company-specific issues and the interest rate environment could impact what yield the market deems irresistibly attractive with a stock. So there went the illusion of fixed goalposts, the Holy Grail, and easy-peasy investing out the window. After all, every company’s business operations are in constant motion, and market yields are also anything but static. Did I really overpay for that restaurant stock? And all this while following expert advice? I was as annoyed as you may have been when first noticing that the entry price recommendations of the FALCON Method can move lower when things change.

As for expert advice, knowing what I know now, I wholeheartedly agree with Scott Adams: “No one has ever followed the advice of another person. People think they follow advice but they don’t. Humans are only capable of receiving information. They create their own advice. If you seek to influence someone, don’t waste time giving advice. You can change only what people know, not what they do.” Based on this observation, let me share some information on what we do at the FALCON Method, how those entry prices are calculated, and what factors influence them.

First of all, analyzing a company means that our team must dissect what the firm is doing to make money. Using Amazon as an example, they have various segments of operations like retail, cloud, and advertising services. Understanding where the revenue comes from, we should assess each field’s profitability along with the underlying markets’ key characteristics (the size of the total addressable market, current penetration, and expected growth rates). Formulating an opinion on how the company’s market position will likely evolve in each segment is also essential when modeling future revenues and margins. This process involves a ton of reading. For example, Alibaba’s margins on third-party selling can be pretty telling about how much money Amazon can make in its corresponding sub-segment. At the same time, Alphabet and Meta can serve as reasonable benchmarks for the profitability of Amazon’s advertising business. (However, one must dive deep into analyzing all the relevant competitors to incorporate these numbers.) When putting together our valuation models, we pay close attention to analysts’ published expectations on the companywide revenue growth. We also consider the underlying markets’ prospected growth and the firm’s position in those segments. (As for Amazon’s ad business, the online advertising market is expected to grow at a CAGR of ~10% over the next five years, while Amazon will most likely gain market share thanks to its first-party transactional data of unique quality. Consequently, modeling a sub-10% revenue growth in the ad segment doesn’t seem sensible at this point.) After a deep examination of all the company’s business areas, we can come up with a range of reasonable revenue expectations for our explicit modeling period (that is five years).

The segment margins may either be disclosed, or peer data might be available to get the ballpark right, so we can venture an educated guess on the companywide profitability and the resulting EVA trajectory. Please note that we always think in ranges, as precise forecasting is impossible. This means we are building an enterprising and a very conservative (dare I say pessimistic) fundamental scenario. For example, in Amazon’s bear case model, we are calculating with zero profitability in the retail segment (which is almost unrealistic) while also tuning down the growth expectations across the company. Once the models of the two scenarios are ready, we must apply the relevant valuation metrics (FGR, in our case) to come up with estimates of enterprise values at the end of our 5-year forecasting period. Next, we convert those to per-share values and calculate the annualized total return potential, including the dividends harvested along the way.

I hope you see that this is more art than science, and plenty of moving pieces can impact a stock’s valuation and total return potential. Revenues, margins, and cost of capital are far from static, just to name a few variables. As for the evolution of the FALCON Method, we used to build only one fundamental model for every company. Then we applied an enterprising and a moderate valuation to that single EVA trajectory to come up with a range of reasonable outcomes. While our one-model approach involved rather conservative numbers, we now have a more realistic and a more pessimistic fundamental scenario, and we apply the corresponding FGRs to both. Since the revenue and margin inputs in our bear case models seem overly restrained, we hope (and probability suggests) that companies will seldom underperform those levels, prompting us to reassess our valuation. Consequently, our punchcard prices should become less volatile, but we refrain from promising fixed goalposts. (As for our entry price recommendations, the higher “start accumulating” level offers a 15% annualized total return potential averaging our two scenarios. The lower “take full position” price provides that 15% return potential in the pessimistic scenario with the corresponding, more depressed valuation multiple.)

We keep learning and aim to earn high returns on our past mistakes. One of 2022’s key lessons was that total return potential doesn’t essentially equal attractiveness. Since getting the qualitative assessment right is overwhelmingly more important with EVA Monsters than the degree of precision on the quantitative modeling side, differences in forecastability and our level of understanding must come into play when ranking investment candidates. A risk-adjusted total return ranking (inevitably involving more subjective inputs) would allow us to present “safer bets” in our Top 10 that can act as anchor positions in a portfolio. Put simply, regardless of how many Chinese companies boast total return potentials above 20%, I would rather go for the likes of Nike, Costco, or Novo Nordisk when the opportunity arises.

Employing this approach can make our Top 10 less static as we may occasionally want to present (and buy) a lower-ranking name that offers enticing risk-adjusted return potential. One thing will never change, though: mistakes remain part of the game. Since we use them to get better, our long-term returns should be more than satisfactory. (Not that our current results weren’t decent.)

Jason Zweig of The Wall Street Journal says there are three ways to earn money as a writer: (1) Lie to people who want to be lied to, and you’ll get rich. (2) Tell the truth to those who want the truth, and you’ll make a living. (3) Tell the truth to those who want to be lied to, and you’ll go broke. As a newsletter provider and born longtermist, I am invariably aiming for option #2, hoping enough investors are out there wanting the truth instead of fancy promises. In this spirit, I will continue sharing well-structured, relevant information so that you can create your own advice and make educated investment decisions.

If you liked this piece, you may also want to take a look at my Confessions of an Ironman book.

You can also find more insights and tips for your investment journey in our Blog.

How Becoming an Ironman Has Made Me a Better Investor

“You can quit if you want, and no one will care. But you will know for the rest of your life.” (John Collins, IRONMAN co-founder)

Ironman is the fancy name of long-distance triathlon that consists of a 2.4-mile (3.8 km) swim, a 112-mile (180 km) bicycle ride, and a 26.22-mile (42.2 km) marathon run, in that order and without a break. By completing two Ironmans, I have gained some valuable insights along the way into how the characteristics required for success in long-distance endurance sports and long-term investing are strikingly similar.

I bet most of you didn’t know that reputable value investor Peter Cundill could run a marathon in under 3 hours, even past his young years. Also, did you notice anything special about Warren Buffett’s 2012 letter to shareholders? That’s the one in which he highlights that Berkshire has a lot of home-grown talent when it comes to sports: Ted Weschler, one of the younger investment managers, has run the marathon in 3:01, while his colleague Todd Combs specializes in triathlon. I believe it is not pure happenstance that some well-known investors are involved in endurance sports, so I’d like to share some parallels and revelations that came to me during those 20-hour training weeks.

Let’s start with the hidden element. Do you think that triathlon consists of only three parts: swim, bike, and run? Wrong. It’s humanly impossible to cross the finish line of an Ironman without following a good race nutrition protocol. This is the hidden element that the more spectacular parts cannot work without, and this field is much more complex than you might imagine. We also have such a crucially important invisible factor in investing: psychology. Anyone can crunch the numbers and do some kind of valuation, but most investors let their inborn biases sabotage their success. Psychology may not sound too exciting, but it still makes up about 90% of the success equation when it comes to investing.

How well can you endure monotony? Running 50+ laps on the track and cycling 90+ laps on a short flat track were part of my preparation. While my friends say they would go crazy if they had to do this, I usually have a great time during these training sessions. I can either switch off mentally and relax or direct my thoughts to something I want to delve deep into. There’s nothing fancy about an Ironman preparation like there is nothing fancy about sensible investing. You don’t change the strategy week in and week out just to get some excitement, and you must be prepared to stick with the boring stuff even when all the others seem to be having a great time. (The boring stuff refers to our hardly changing Top 10 of undervalued quality stocks in this overheated market.) Enduring monotony is essential to becoming a successful investor; chasing fads is detrimental to your wealth.

What about pain? In my experience, every big goal in life that is worth pursuing keeps asking along the way how bad you want it. Nothing comes easy, and the excuse to give up lurks around every corner. Let me be as straightforward as possible: you will have to endure suffering along the way to financial freedom. Neither sporting nor financial success can be achieved without pain. Only those who can keep buying the out-of-favor quality stocks when there’s blood in the streets will reach their goals. This is easier said than done; don’t say I didn’t warn you! I believe that I am mentally tougher than most people, and I often experience this at both triathlon races and stock investing. Sebastian Kienle, the 2014 Ironman World Championship winner, puts it this way: “If it’s hurting me, it’s killing them.” When it starts to really hurt me, the market has already fallen apart, and others have capitulated.

We are judged by what we finish, not what we start. Starting strong is meaningless if you cannot keep up the pace and thus end up quitting halfway through the race. Do you think it’s easy to find your own pace and stick to it no matter what the others are doing on the race track? Think again! Just like it is incredibly hard not to deviate from your investment plan when others are getting rich with seemingly ridiculous speculative bets, it also requires discipline not to follow the crowd at a race. My first competitive marathon taught me this lesson in an unforgettably painful way. Know your sustainable pace, have a plan, and stick to that plan no matter what!

You will only achieve your big goals if you learn to enjoy the way that leads to them. Yes, it will involve pain and suffering, but it also gives you a chance to get to know your true self. There’s a saying that “Triathlon doesn’t build character. It reveals it.” Keep monitoring your state of mind, and you can learn so much along the way that the race becomes a celebration of all your efforts and accomplishments. Your investment journey will also serve as a mirror that won’t do you any favors in the form of positive distortions. Are you prepared for what you’ll see?

No matter your goals, you must take 100% responsibility for all your actions and stop blaming circumstances outside your control. Those circumstances may affect others as well; it’s your reactions that determine your results. No excuses; you have to keep moving, “this marathon will not run itself,” as I usually say when I am unwilling to stop regardless of how I feel. Setbacks do happen; it’s up to you to make the most of them, learn the lessons, and come back stronger. If you have the determination and perseverance, you can become financially free, an Ironman, or whatever you set your sights on. It’s only a matter of time.

The key is setting the proper goals since you can have anything you want but not everything! You’ll need to prioritize, and after having your clear number one goal, it is wise to learn from someone who has already done what you are aiming for. This approach lets you proceed toward that goal on a somewhat less bumpy road at a higher-than-normal speed. This is exactly what the FALCON Method Newsletter is intended to help you with regarding your investments, and this is why I was following a training plan created by a professional triathlete with my Ironman preparation. Once you cross the finish line (achieve financial freedom, that is), you’ll realize that what you have learned and experienced along the way is much more valuable than reaching the goal itself. That knowledge is yours to keep forever, and you can share it for the benefit of your loved ones. The journey is the destination, as they say. It is time to stop wishing for that goal and start working for it.

If you liked this piece, you may also want to take a look at my Confessions of an Ironman book.

You can also find more insights and tips for your investment journey in our Blog.

The EVA Monster Series: The Unseen Hand Guiding the Digital Revolution

With this series, we’d like to give you some perspective on the companies in our distinguished EVA Monster universe. This rare breed of quality-growth stocks is worthy of your attention, and getting to know these businesses may pay off handsomely down the road.

As a quick recap, EVA Monsters have three things in common:

  • They earn high returns on the capital they employ.
  • They have growth opportunities that allow them to reinvest most of their cash flows at high rates of return.
  • They have a sustainable competitive advantage (that Warren Buffett calls “moat”), which prevents their competitors from taking away their extraordinary profitability.

These characteristics tend to result in a strong (double-digit) fundamental return potential, meaning that no valuation tailwind is necessary to get great investment results with EVA Monsters. (These case studies explain this pretty well.)

As Charlie Munger said:

“Over the long term, it’s hard for a stock to earn a much better return that the business which underlies it earns. If the business earns 6 percent on capital over 40 years and you hold it for that 40 years, you’re not going to make much different than a 6 percent return – even if you originally buy it at a huge discount. Conversely, if a business earns 18 percent on capital over 20 or 30 years, even if you pay an expensive looking price, you’ll end up with one hell of a result.”

We also shared the math proof of why buying EVA Monster stocks at a fairish valuation makes perfect sense for long-term investors. (Look for the “math example” in this post to alleviate your doubts.)

To round off the short introduction, we (1) try to avoid overpaying for EVA Monsters, (2) closely monitor the fundamental performance and management’s capital allocation decisions throughout our holding period, and (3) hold our positions as long as the underlying investment thesis remains intact, ideally for decades, to let compounding do the heavy lifting.

Without further ado, numbers prove that Accenture (ACN) is a true EVA Monster, and building a position in the company would be a great way to get indirect exposure to the overall digitalization megatrend.

Accenture is a leading global professional services company that assists businesses and other organizations in constructing their digital core, optimizing their operations, and accelerating revenue growth. Its activities include strategic management consulting, technology services (e.g. implementing cloud transformation), and managing back-end systems such as finance and accounting, procurement, or human resources. Additionally, the firm offers adjacent services in engineering and advertising strategy. The company was founded in 1951 and is based in Dublin, Ireland.

The company began as the business and technology consulting division of the accounting firm Arthur Andersen in the early 1950s. It was headed by the renowned engineer and inventor Josepf Glickauf, one of the first advocates of using computers in business and the “father” of the computer consulting industry. In 1989, Arthur Andersen and Andersen Consulting became separate units. After a long and bitter dispute, the latter gained independence and changed its name to Accenture in 2001.

As complex as Accenture’s business model may appear, its essence is rather simple: it monetizes the working hours of its staff with a markup. This added value is facilitated by the continually nurtured expertise, predominantly in highly skilled fields, emphasizing the implementation of new technologies for its clients.

Revenue generated from the cloud transformation of its customers constitutes the largest portion of Accenture’s top line (~42% as of fiscal 2022), encompassing activities such as data migration, modernizing enterprise resource systems, and enhancing AI capabilities. Closely associated is cybersecurity (~10%), spanning from threat intelligence to managed security services. From a different perspective, Accenture’s revenue streams involve 13 distinct industry groups (such as consumer goods, software & platforms, and insurance), each generating over $1 billion in revenue, with none responsible for more than 15% of companywide sales. The firm’s revenue is roughly evenly divided between consulting arrangements, typically lasting less than 12 months, and managed services contracts, usually spanning several years.

At first sight, Accenture’s competitive advantage appears hard to grasp, as, unlike technology companies, it does not have blockbuster products to offer, such as Microsoft Office or Adobe Photoshop. Its competitive edge can be best understood by considering its know-how flywheel.

The firm uses its vast resources to build expertise mainly in emerging digital technologies, spreads the cost over several hundred thousand employees, and offers consulting services for mission-critical applications at a premium to its own labor cost. Specifically, the firm’s treasure trove of experience in serving various industries enables it to offer tailored solutions for highly specialized application areas.

We believe that the two-step business model provides a unique way to extend client relationships and, ultimately, the lifetime revenue realized from a specific project. In a nutshell, after using Accenture’s consulting services to integrate a new system, customers can opt to have it managed by the company in subsequent years. This creates undeniable switching costs, as it is unlikely that a client will transition the outsourced management of an existing system to a competitor unfamiliar with it and risk day-to-day operations.

All this results in exceptional customer loyalty, as 98 of Accenture’s top 100 clients have been with the company for over a decade, turning to its consultants repeatedly through business cycles and technology shifts.

It is evident that the capital-light nature of the underlying business, coupled with significant pricing power, results in exceptional quantitative metrics. Accenture stands firmly above the market’s average, boasting ROC levels in the 30-40% range and an EVA Margin of around 10%. The diversified and largely recurring revenue streams support the thesis that the firm deserves a wide-moat classification.

Source: ISS EVA, The FALCON Method

As for the future, the IT and business services sector is likely to continue its GDP+ expansion trajectory, as the digitalization of businesses through cutting-edge technologies is a nearly endless source of growth. Accenture’s management estimates that within its client base, 40% of workloads are in the cloud, only one-third have modernized their enterprise resource planning (ERP) platforms, and less than 10% have mature data and AI capabilities.

Turning to capital allocation, Accenture typically reinvests around 40-50% of its internally generated cash at exceptional ROC figures. Part of it goes to building new competencies and know-how in-house, but acquisitions remain the primary use of reinvested cash. We really like the firm’s acquisition strategy of extending competencies through smaller, bolt-on acquisitions in high-growth areas and then leveraging the knowledge base to bolster organic growth. This strikes us as a low-risk, high-reward way of enhancing Accenture’s competitive position and growth profile.

Accenture’s cash-generative, capital-light model means that, besides reinvesting, there is plenty of cash left to distribute to shareholders. The company has maintained a 19-year dividend-raising streak, with healthy growth rates and a safe payout ratio. Although the current entry yield of 1.7% is far from glamorous, it is still above the market average. The firm is also a regular repurchaser of its shares, but we have reservations about the opportunistic nature of this activity, as Accenture has not abandoned buybacks even when the stock seemed significantly overpriced.

Looking at the stock’s valuation, Accenture’s stock has been highly rated since 2016, as the market appreciates its operational stability, diversified customer base, and attractive growth runway, all with a low probability of disruption to its business model. Please see below the valuation metrics of the EVA framework that remedy accounting distortions to give us a clearer picture on where the stock stands in a historical context.

(Curious why we don’t use the most popular multiples? Find out here!)

When comparing today’s valuation to historical averages, there appears to be a healthy dose of optimism surrounding the stock, even though the market-relative valuation seems fair. With the baked-in EVA growth of nearly 13% over the next decade, we believe now is not the time to get excited. The 5-year total return potential chart speaks for itself.

Source: ISS EVA, The FALCON Method

The FALCON Method can identify much better opportunities in the current market, so we are passing up on Accenture for now.

The verdict

One of the most prominent challenges Accenture faces is keeping up with the pace of innovation in the technology sector. To remain the consultant of choice, the firm must either build internally or acquire the skills needed to stay at the forefront of its industry. While management understands this source of competitive advantage very well, the fact that Accenture “jumps” on every new trend means there will surely be some dead ends along the way, with areas that don’t develop as management hopes (let’s see where the metaverse goes, for instance). This should be considered a cost of doing business.

The composition of Accenture’s employee base also carries a certain level of uncertainty, with more than half of its workforce residing in India or the Philippines, where the base salary is relatively low (~$7,000 per year) and attrition is notably higher than at most U.S. firms. Moreover, since the company basically follows a cost-plus-margin business model, upward pressure on compensation will translate to higher prices for its customers, which could hinder growth.

While challenges like new competition from cloud service providers or potential harm to the company’s reputation do pose threats, we would be more than willing to buy shares at the right valuation. Despite their risks, the growing importance of cloud-based solutions and the AI revolution could bode well for the company’s consulting services as the technology landscape becomes increasingly complex. We think the firm’s proven, resilient business model, enviable ROC metric, and double-digit fundamental return potential translate to a bright future. As for position sizing, we would be comfortable with a 3-5% exposure.

The company ranked 26th of our 60 EVA Monsters at the time of writing, based on its 5-year total return potential. (Businesses from 12 countries are represented on our EVA Monster list.)

It is safe to say that there are far more attractive EVA Monster stocks to buy in the current market, with the highest-ranking ten boasting total return potentials above 14% over our modeled 5-year timeframe. (You can always find the monthly Top 10 in the FALCON Method Newsletter along with our entry price recommendations.)

Want to learn more about our ranking methodology? Start with this blog post!

You can also learn more about our stock-picking process and follow David’s evolution in the Beyond Dividends book.
No theoretical, academic lessons. Only practical advice and conclusions, delivered in an easy-to-digest, entertaining way to keep you captivated from the first page to the last.
Fast-track your evolution and get to the next level as an investor with Beyond Dividends.

Coat-tailing Done Right

“You can borrow someone’s ideas but not their conviction.”

Several members sent us anxious emails after learning that “superinvestor” Mohnish Pabrai had sold ~80% of his Alibaba holding during the third quarter of 2021. While monitoring the 13F filings of renowned investors may be useful, we never advocated mindless coat-tailing, so let us share the thought process that runs through our minds when we bump into news like this.

We wholeheartedly agree with Bill Nygren of Oakmark Funds, who says, “the reason people have so much trouble with the sell decision is because they didn’t have a well-defined buy decision. If you really know why you decide to buy a stock and why you own it, then the absence of those reasons becomes the reason to sell.” At the FALCON Method, we didn’t just copy Pabrai and the other “superinvestors” (in fact, we had bought Alibaba before most of them disclosed their positions); we did our homework and built the investment thesis from scratch. One should only use the 13F info as input to start their independent analysis since borrowing an idea is seldom enough to take you to the finish line; you will need conviction.

After days of in-depth analysis, our team of analysts tends to invest a couple of hours in summarizing the investment thesis, identifying the most important drivers of performance, and listing the key metrics to monitor with every company. We also put together a short and simple premortem that forces us to build out that side of the probability tree where things don’t work out. It’s important to note that the premortem process occurs before an investment decision is made. We basically assume that we are in the future and the decision we made has failed. We then provide plausible reasons for that failure. Psychologist Gary Klein’s research shows that premortems help people identify more potential problems than other techniques and encourage more open exchange because no individual or group has yet invested in a decision. Without a premortem, we don’t see as many paths to the future in which we don’t reach our goals, while in reality, that can be a pretty robust part of the probability tree.

Once we are done with this process, we know exactly what to monitor closely with each and every company we invest in. As for Alibaba, the number of active China accounts and the gross merchandise value give us valuable clues on the level of disintermediation risk, while the cloud segment’s revenue, margin expansion, and market share dynamics may show how the “Amazon
story” is playing out. We have minimum thresholds for revenue and EVA per share growth, as well as for the EVA Margin, and the violation of these levels would prompt us to revisit our thesis. That said, we don’t believe that a single quarter’s results could be enough to make us change our minds.

The first thing we tend to check when news like Pabrai’s sale hit our mailbox is whether our well-defined investment thesis is broken. All in all, the list of valid reasons to sell a stock is relatively short: (1) We were wrong, (2) the stock became overvalued, (3) or we have a much better investment idea and need to free up capital. With Alibaba, number one is too early to call. Number two seems out of the question unless we assume the imminent collapse of the firm’s fundamental business performance. As for reason number three, the bar set by Alibaba’s total return potential looks way too high to justify a sell decision at this point.

Before moving on, we’d like to remind you that widely acclaimed investors will never call you before they sell (or buy) a stock, so managing your portfolio does require independent thinking and conviction that is based on in-depth analysis. Your emails reveal that most of you think Pabrai must have some insider information that led him to reduce his Alibaba position. While he may have an even better investment idea, history proves that selling a compounder is almost always a mistake. Warren Buffett’s Disney and McDonald’s investments come to mind, but you can also think of how Carl Icahn missed out on tremendous amount of gains by selling Netflix and Apple, or how Fundsmith’s Terry Smith screwed up with his Domino’s Pizza exit. Yes, Virginia, even “superinvestors” make such costly mistakes, which shows that they seldom (if ever) have that kind of insider info you suspect to guide their decision-making. Joseph P. Kennedy, former chairman of the Securities and Exchange Commission, whose son was President of the United States, put it perfectly: “If I had all the money that has been lost on inside information, I’d really be rich.”

As for managing EVA Monster positions, Howard Marks’ thoughts come to mind: “There’s a joke going around that in the factory of the future there is one man and one dog. The dog’s job is to keep the man from touching the equipment, the man’s job is to feed the dog. Most investors, in the same way, need a dog that has the job of keeping them from putting their hands on the portfolio.” We believe that we are best served by doing nothing as long as the EVA Monster characteristics of a business remain intact. If it feels uncomfortable holding Alibaba at this point, rest assured that this is, by definition, part of successful investing. (If your sleep is ruined, you may have to revisit your position sizing, though.)

Many of you keep asking us about the evolution of the FALCON Method and whether we are abandoning the income-focused approach we employed back when this service started. We are always on a hunt for quality dividend payers that are marked down. As the years went by, however, the pricey institutional-level data clearly supported our experience that there was a strong correlation (82%, to be more exact) between where EVA (Economic Value Added) goes and the level of shareholder returns. Take a look at this picture and see some examples to alleviate your doubts.

Source: ISS EVA, The FALCON Method

Investing for income alone is a mistake, the price of which is a subpar total return that negatively affects one’s future purchasing power. While we love passive income, only a snake oil salesman would try to persuade you that quality dividend payers are attractively priced in today’s market. Please do yourself a favor, and relinquish your focus on the entry dividend yield parameter as long as the scarce breed of high-quality growth companies may be the last mispriced assets. (Since it is almost impossible to overprice them based on the near-term multiples that most investors are fixated on).

If you found this article helpful, be sure to check out our Blog for more insights and tips for your investment journey.

The EVA Monster Series: Biotech Exposure with a Twist

With this series, we’d like to give you some perspective on the companies in our distinguished EVA Monster universe. This rare breed of quality-growth stocks is worthy of your attention, and getting to know these businesses may pay off handsomely down the road.

As a quick recap, EVA Monsters have three things in common:

  • They earn high returns on the capital they employ.
  • They have growth opportunities that allow them to reinvest most of their cash flows at high rates of return.
  • They have a sustainable competitive advantage (that Warren Buffett calls “moat”), which prevents their competitors from taking away their extraordinary profitability.

These characteristics tend to result in a strong (double-digit) fundamental return potential, meaning that no valuation tailwind is necessary to get great investment results with EVA Monsters. (These case studies explain this pretty well.)

As Charlie Munger said:

“Over the long term, it’s hard for a stock to earn a much better return that the business which underlies it earns. If the business earns 6 percent on capital over 40 years and you hold it for that 40 years, you’re not going to make much different than a 6 percent return – even if you originally buy it at a huge discount. Conversely, if a business earns 18 percent on capital over 20 or 30 years, even if you pay an expensive looking price, you’ll end up with one hell of a result.”

We also shared the math proof of why buying EVA Monster stocks at a fairish valuation makes perfect sense for long-term investors. (Look for the “math example” in this post to alleviate your doubts.)

To round off the short introduction, we (1) try to avoid overpaying for EVA Monsters, (2) closely monitor the fundamental performance and management’s capital allocation decisions throughout our holding period, and (3) hold our positions as long as the underlying investment thesis remains intact, ideally for decades, to let compounding do the heavy lifting.

Without further ado, numbers show that Veeva Systems (VEEV) is a genuine EVA Monster, so it is worthy of your close attention. We consider the firm to be a perfect long-term play on the growing importance of the life sciences industry without being exposed to any degree of pipeline risk inherent in every pharma company.

Veeva is a leading global provider of industry-specific, cloud-based software solutions for the life sciences industry. Its offerings include cloud software, data, and business consulting, all designed to meet customers’ unique needs and address their most strategic business functions, from research and development (R&D) to commercialization. Veeva’s solutions help life science companies develop and bring products to market more quickly and efficiently, enabling effective marketing and sales while maintaining compliance with government regulations.

In 2007, Peter Gassner founded Veeva as a verticalized Customer Relationship Management business built on top of Salesforce and custom-made for the life sciences industry. Gassner had the original insight while working at Salesforce as VP of Technology and saw their limitations as a horizontal platform. He profoundly impacted the pharma industry by introducing a brand-new SaaS solution to the market, and he has been serving as CEO ever since Veeva’s founding.

Subscription fees are Veeva’s primary revenue source, contributing 80% to the top line as of fiscal 2023. These fees encompass Software as a Service (SaaS) revenues, roughly evenly distributed between commercial and R&D offerings.

Veeva Commercial Cloud represents a product family comprising software and data services tailored specifically for life sciences companies aiming to enhance the efficiency and effectiveness of their product commercialization processes by offering solutions for sales, medical affairs, and marketing functions. Conversely, the firm’s R&D solutions target the clinical, regulatory, quality, and safety functions, assisting life sciences companies in streamlining their end-to-end product development processes. This, in turn, promotes increased operational efficiency and ensures regulatory compliance throughout the product life cycle.

While its customer base is concentrated in the biopharma industry, Veeva serves a diverse array of over 1,000 enterprise clients. These range from the largest global pharmaceutical and biotechnology firms, such as Eli Lilly, Gilead Sciences, and Merck, to emerging startups in the field.

Veeva has established a moat around its business by differentiating itself from generic Customer Relationship Management (CRM) providers. Specializing in the life sciences industry, the firm embodies all the characteristics of a typical Vertical Market Software (VMS) provider. Generally, such solutions handle mission-critical applications in their clients’ businesses, thereby incurring substantial switching costs.

What distinguishes Veeva is its highly cohesive product ecosystem, spanning from commercial (cloud, data, analytics) to R&D solutions (clinical, quality, regulatory, safety). In essence, Veeva’s platform consolidates traditionally siloed and disconnected workflows, enabling its customers to manage the entire lifecycle of a clinical trial, from molecule discovery to commercialization. While competitors do offer some similar solutions, no product on the market can match the firm’s comprehensive platform, which is its primary advantage.

Because the total cost of Veeva’s software suite amounts to approximately 1% of its customers’ annual revenue, there is little incentive to switch to a competing solution and potentially risk business disruption. The company’s retention rate has exceeded 100% over the past few years, indicating that its customers not only renew but also increase their purchases each year, with few subscription cancellations.

Overall, the company undeniably deserves a wide-moat classification from a qualitative standpoint. It also excels in meeting our quantitative criteria, displaying robust double-digit ROC and EVA Margin figures. Alongside evident pricing power and a lucrative clientele, the underlying dynamics in life sciences contribute to these outstanding profitability metrics.

Source: ISS EVA, The FALCON Method

As for the future, Veeva’s life sciences end markets represent a large and growing pie, with the biopharma and medical technology sectors estimated to expand at a mid-single-digit annualized rate over the long run. Industry-specific software and data solutions will likely exhibit higher growth rates as the segment becomes more technologically enabled. The firm’s prospective customers are eager to replace their in-house legacy software or general-purpose CRM tools with Veeva’s cloud-based solutions focused on life sciences. According to management, the firm has penetrated just over 10% of its addressable market, leaving ample room for future share gains.

Turning to capital allocation, Veeva typically reinvests about 40% of its internally generated cash and achieves magnificent ROC figures north of 50%. R&D is generally the most significant use of capital as the company continues to release new product categories (like Vault and QualityOne) and add-on modules, paired with smaller, tuck-in acquisitions that management considers complementary to the product portfolio.

The picture is pretty bleak on the shareholder distribution front. Veeva has never paid a dividend (which is unlikely to change anytime soon), and it has spent only a negligible amount on share buybacks since its IPO. This has two consequences. (1) As the reinvestment rate is below 100%, and virtually no money is returned to shareholders, the firm’s cash balance has grown from $300 million in 2014 to over $4 billion as of today. (2) The share count keeps rising due to the dilutive effect of employee equity grants, increasing by ~13% in aggregate since the IPO. Despite management’s indisputable “efficiency focus,” Veeva is granting enormous stock-based compensation packages, resulting in an average annual dilution of over 2% per annum (way above our not-so-strict threshold of 1%).

Looking at the stock’s valuation, in Veeva’s case, we don’t consider historical multiples to be a good forward-looking proxy, given the company’s material increase in size over the past 5-10 years, while its growth rate has (naturally) come down. Please see below the valuation metrics of the EVA framework that remedy accounting distortions to give us a clearer picture on where the stock stands in a historical context.

(Curious why we don’t use the most popular multiples? Find out here!)

Regardless of how we look at it, the stock appears very expensive on a market-relative basis with its 2.6% NOPAT Yield. The 10-year baked-in EVA growth is also near 20% at the current price, which we deem extreme.

Overall, the time to get excited is not now. The “Key Data” table and the 5-year total return potential chart speak for themselves.

Source: ISS EVA, The FALCON Method

The FALCON Method can identify much better opportunities in the current market, so we are passing up on Veeva for now.

The verdict

The most prominent short-term risk factor to consider is Veeva’s intent to migrate its CRM business from Salesforce’s platform to its own Vault system by 2025, which might raise customer concerns and lower retention rates. Mishandling this migration could lead to disruptions or loss of certain data, posing serious trouble for Veeva’s customer base. Currently, the firm generates ~30% of its revenues from products built on top of Salesforce’s platform, making it worth monitoring.

Since nearly all of Veeva’s revenues come from sales to customers in the life sciences industry, the business exhibits a heightened level of macroeconomic sensitivity. This is precisely the situation of late, as the bleaker macro picture has led to a challenging funding environment (or outright bankruptcies in some cases) for Veeva’s smaller biotech customers who use the company’s R&D solutions. Such difficulties have impacted, and may continue to impact, Veeva’s operating results.

While challenges like data breaches, mishandling of sensitive information, or regulatory interventions do pose threats, we would be happy to scoop up this EVA Monster at the appropriate price. Its SaaS model is extremely lucrative, the moat is unquestionably there, and the growth outlook remains bright. Although the excessive stock-based compensation and lack of shareholder returns are far from ideal, these alone do not warrant sidestepping the stock. As for position sizing, we see no reason to go below a 3-5% position size target.

The company ranked 35th of our 59 EVA Monsters at the time of writing, based on its 5-year total return potential. (Businesses from 12 countries are represented on our EVA Monster list.)

It is safe to say that there are far more attractive EVA Monster stocks to buy in the current market, with the highest-ranking ten boasting total return potentials above 12% over our modeled 5-year timeframe. (You can always find the monthly Top 10 in the FALCON Method Newsletter along with our entry price recommendations.)

Want to learn more about our ranking methodology? Start with this blog post!

Curators of Wealth

“Our attitude is that of a museum director: we only want to own masterpieces.” (François Rochon)

Chances are that, just like us until a couple of weeks ago, you have never heard of Giverny Capital, even though the name might sound familiar. It was inspired by one of the most breathtaking gardens in the world, created and cared for over many decades by Claude Monet, the pioneer of the Impressionist movement. François Rochon is a Canadian investor and the founder, long-term president, and portfolio manager of the Montreal-based firm. We are bringing him up because we recently came across his annual letter celebrating the 30th anniversary of his flagship fund, the Rochon Global Portfolio. Such longevity is rare among asset managers, making him one of the most seasoned investors with a quality-growth focus.

Rochon’s investment philosophy revolves around owning a small number of great companies for the long term. Emulating the dedication required to preserve Monet’s garden, his mission is to create wealth through thoroughly selected, high-quality securities. As he once noted, “Our attitude is that of a museum director: we only want to own masterpieces.” Rochon aims to hold around twenty companies in his portfolio, with an average holding period exceeding seven years. He strives to remain unfazed by the vicissitudes of the economy, geopolitics, and financial markets, remaining fully invested at all times and accepting that trying to time the market is a fool’s errand. The Rochon Global Portfolio has returned a whopping 14.8% annually over a period of 30 years, compared to 10.2% for the S&P 500. Even if we consider that these are pre-fee results (which would deduct about 1 percentage point), the outperformance gap speaks for itself.

You might start to wonder whether, with such long average holding periods, this investment performance should exhibit some correlation to the underlying fundamental results of the companies in Rochon’s portfolio. We believe the single most valuable takeaway from his annual letters is an incredibly long track record of the fundamental performance of his portfolio constituents going back almost to the fund’s inception. Since 1996, he has included a summary table in each year’s report containing the growth in the intrinsic value of his companies, using Warren Buffett’s “owner’s earnings” approach. He estimates the increase in the intrinsic value of his holdings each year by adding the growth in EPS and the average dividend yield of the portfolio. This analysis is not exactly bulletproof (we would prefer EVA-based metrics); still, it is approximately correct over multiple decades. In fact, between 1996 and 2023, Rochon’s portfolio constituents have grown their intrinsic value by 12.9% annually, matching the 12.9% annualized return their stocks have produced over this timeframe. Of course, the figures could deviate significantly in a single year due to fluctuations in valuation, but the long-term trajectory is self-evident.

We have long known that investment returns are determined by the fundamental performance of the underlying companies in a buy-and-hold portfolio. Seeing such quantitative evidence in a real-world setting was nevertheless reassuring. The longer the holding period, the closer your returns will match the underlying companies’ fundamental return, but this is by no means a green light to be valuation-agnostic, as you can be right about the success of a business without necessarily achieving a good return on your investment when you lack caution regarding the price paid.

No wonder Rochon’s analysis made us curious about how the EVA Monsters within our investable universe fare in a similar backtest. We chose a timeframe of ten years, as it seemed like a fair compromise between a long enough period and sufficient company data, given that a substantial number of names have barely longer track records as public entities. We compiled a hypothetical equal-weighted portfolio in 2014 (investing $1,000 in each company) and computed the look-through EVA for the group. We repeated this exercise for today as well, keeping the same number of shares from each company and letting them “run freely” over the period. Note that the look-through EVA contains the impact of share repurchases as well, as it is computed using the aggregate EVA per share figures of the portfolio constituents at both points in time. We also added our estimate of the average dividend yield of the companies as the best proxy to model the contribution of dividend payments. The results were staggering: our EVA Monster universe delivered an annualized total return of ~23%, of which ~21% can be attributed to the fundamental return component. For reference, the S&P 500 has delivered a ~12% annualized total return over this timeframe, out of which the fundamental return explains ~9%.

Two major takeaways to note from this comparison: (1) the fundamental return of the EVA Monster universe has been head and shoulders above the market’s average. One could argue that there is survivorship bias (since we composed our universe based on exceptional backward-looking fundamental performance), but we contend that these companies also have excellent prospects going forward, even though the gap will likely narrow to the S&P 500. (2) The impact of valuation is quite similar in both groups (2 percentage points tailwind for the EVA Monster universe and 3 for the S&P 500). Its contribution is rather modest in both cases, and it would likely diminish over multiple decades, as shown by Rochon’s analysis.

It’s crucial to understand that two equal total return potentials could vastly differ in composition. We are talking about two completely different investment scenarios depending on whether the fundamental return or the change in the valuation multiples is the key contributor. On the one hand, we deem our EVA Monsters capable of delivering double-digit fundamental returns for years to come. These firms are best suited for true buy-and-hold investing, which requires judging the sustainability of above-average fundamental performance and trying to avoid overpaying. On the other hand, the typical Fallen Angel investment thesis is about an expected recovery in valuation multiples, leading to an attractive total return potential despite the (more often than not) subpar fundamental performance outlook. Remember, though, that a valuation rebound is a one-trick pony. In either case, the longer you hold onto these names, the higher the chance that your performance will converge to the underlying fundamental performance of your holdings.

If you found this article helpful, be sure to check out our Blog for more insights and tips for your investment journey.

The EVA Monster Series: A Recipe for Sizzling Returns

With this series, we’d like to give you some perspective on the companies in our distinguished EVA Monster universe. This rare breed of quality-growth stocks is worthy of your attention, and getting to know these businesses may pay off handsomely down the road.

As a quick recap, EVA Monsters have three things in common:

  • They earn high returns on the capital they employ.
  • They have growth opportunities that allow them to reinvest most of their cash flows at high rates of return.
  • They have a sustainable competitive advantage (that Warren Buffett calls “moat”), which prevents their competitors from taking away their extraordinary profitability.

These characteristics tend to result in a strong (double-digit) fundamental return potential, meaning that no valuation tailwind is necessary to get great investment results with EVA Monsters. (These case studies explain this pretty well.)

As Charlie Munger said:

“Over the long term, it’s hard for a stock to earn a much better return that the business which underlies it earns. If the business earns 6 percent on capital over 40 years and you hold it for that 40 years, you’re not going to make much different than a 6 percent return – even if you originally buy it at a huge discount. Conversely, if a business earns 18 percent on capital over 20 or 30 years, even if you pay an expensive looking price, you’ll end up with one hell of a result.”

We also shared the math proof of why buying EVA Monster stocks at a fairish valuation makes perfect sense for long-term investors. (Look for the “math example” in this post to alleviate your doubts.)

To round off the short introduction, we (1) try to avoid overpaying for EVA Monsters, (2) closely monitor the fundamental performance and management’s capital allocation decisions throughout our holding period, and (3) hold our positions as long as the underlying investment thesis remains intact, ideally for decades, to let compounding do the heavy lifting.

Without further ado, numbers prove that Rational AG (RTLLF) is a great EVA Monster candidate despite the no-moat nature of its industry, so it is worthy of your close attention. This market leader boasts stellar quantitative metrics, and our qualitative assessment also supports a wide-moat badge in its niche market.

Rational AG develops, produces, and sells professional cooking appliances for industrial kitchens worldwide, serving restaurants, communal catering clients, and retail chains. The company’s flagship offerings are the iCombi combi-steamers and iVario multifunctional cooking systems, designed to replace conventional cooking appliances such as stoves, grills, and ovens.

Siegfried Meister founded what is now Rational AG in 1973. For 44 years, he led his life’s work to success and remained true to his motto of focusing on customer benefit. Although he passed away in 2017, his values are still firmly embedded in the corporate culture today. His dear friend, Walter Kurtz, also played a crucial role in turning Rational into a success story, and he still holds a significant ownership stake in the business.

The majority of Rational’s top line (70% as of fiscal 2023) comes from the sales of its multifunctional cooking systems. The flagship product is called iCombi Pro, a combi-steamer with intelligent, software-controlled cooking paths, where heat is transferred by steam and hot air to achieve the desired result. The remaining portion of the company’s top line (30%) stems from aftermarket sales, including accessories, spare parts, and maintenance services for its cooking appliances.

Rational has long been a pioneer in its field, establishing the combi-steamer category almost 50 years ago. Ever since, the firm has remained the global market and technology leader in innovative solutions for thermal food preparation in the world’s professional kitchens, boasting a market share of around 50%, roughly five times greater than its closest competitor.

Even though the purchase of a combi-steamer represents a significant capital outlay for its clients, it is widely regarded as an investment with exceptional returns, resulting in payback periods of just a few months and ROI figures well over 100%, which explains the relentless demand for Rational’s appliances.

Additionally, Rational’s appliances have a reputation for reliability and German quality, coupled with a market-leading warranty program. The firm also offers a global service network with 24/7 availability, enabling it to minimize expensive downtime for its clients. Rational has stayed at the forefront of innovation for decades, allocating 5% of its sales on average toward R&D.

Overall, despite being a significant investment from its customers’ side, Rational’s ecosystem and its array of value-added offerings represent a lower total cost of ownership compared to traditional appliances and competitors. compared to traditional appliances and competitors.

Source: ISS EVA, The FALCON Method

As for the future, as prosperity increases worldwide, the restaurant and catering sector gains more importance because it materially contributes to the standard of living for the expanding global middle class. Consequently, the number of quality meals that need to be prepared every day around the world continues to grow. All of this results in the restaurant sector growing at a GDP-beating pace for years to come, serving as a baseline growth rate for appliance suppliers as well.

We argue that Rational will likely continue to outgrow the broader market, propelled by the powerful tailwind of combi-cookers replacing traditional technology in professional kitchens. Based on management’s estimates, there is ample untapped market potential for both of its product groups, with iCombi and iVario serving roughly 12% and 2% of their addressable markets, respectively.

As for capital allocation, Rational typically operates with a very low reinvestment rate of 10-15%, while ROC figures have averaged a staggering 45%. The company also maintains a very solid balance sheet with more than sufficient liquidity and zero debt.

As for shareholder distributions, since the business requires minimal incremental capital to operate and grow, most of the surplus cash can be paid out as dividends. Although the firm has declared a payout every year since its IPO, the amount has been quite irregular because management adheres to a 70% payout ratio, regardless of the yearly profit. Special dividends have also been occasionally announced when there was no better use of cash.

Looking at the stock’s valuation, Rational’s stock has always been extremely highly rated, except during market downturns like the 2008-09 recession or the COVID crisis in 2020. In other words, if you look solely at the growth characteristics of the business, you could have seldom bought this stock at a seemingly sensible valuation. Please see below the valuation metrics of the EVA framework that remedy accounting distortions to give us a clearer picture on where the stock stands in a historical context.

(Curious why we don’t use the most popular multiples? Find out here!)

At this price, the market anticipates a 20% EVA growth annually over the next 10 years, which is nearly impossible to justify. The 2.4% NOPAT Yield is also starkly below the market average of 4.0%.

Overall, the time to get excited is not now. The “Key Data” table and the 5-year total return potential chart speak for themselves.

Source: ISS EVA, The FALCON Method

The FALCON Method can identify much better opportunities in the current market, so we are passing up on Rational for now.

The verdict

When assessing the most influential risk factors surrounding this investment thesis, we must first mention that Rational is sensitive to short-term macroeconomic headwinds. An unfavorable macro landscape can reduce restaurants’ willingness to invest in new equipment, such as combi-steamers, while the pace of new openings is also subdued in times of economic turmoil.

The competitive landscape might also change. For now, most direct competitors are small, private companies lacking the firepower to match Rational’s R&D investments. However, meaningful industry consolidation could spawn better-capitalized entities that theoretically would be able to catch on in technological development.

Despite these possible threats, we would happily add this family-owned, disruption-proof EVA Monster to our FALCON Portfolio at a price where the valuation component becomes a tailwind, even though the ~10% fundamental return outlook barely surpasses our minimum requirement. Regarding position sizing, we remain cautious, aiming for a 2-3% exposure.

The company ranked 42nd of our 59 EVA Monsters at the time of writing, based on its 5-year total return potential. (Businesses from 12 countries are represented on our EVA Monster list.)

It is safe to say that there are far more attractive EVA Monster stocks to buy in the current market, with the highest-ranking ten boasting total return potentials above 13% over our modeled 5-year timeframe. (You can always find the monthly Top 10 in the FALCON Method Newsletter along with our entry price recommendations.)

Want to learn more about our ranking methodology? Start with this blog post!

Keep It in the Family

“If a restaurant has an absentee owner, over time the service quality will slip and the waiters will have their hand in the till.” (Robert Vinall)

Our goal with exceptional quality-growth businesses is to become long-term owners. This essentially means that we are entrusting the custody of our capital to the right people, preferably at the right price. As Fundsmith’s Terry Smith notes, “When you choose to invest with us on behalf of your clients, you’re subcontracting their capital to us to look after. The reality of this process is that we subcontract it to the management of companies.” In the long run, our investment performance will depend heavily on whether these management teams are exceptional stewards of shareholders’ capital or squander opportunities for the sake of short-termism and pleasing Wall Street.

We believe that founding families having a substantial ownership stake tilts the odds in our favor by aligning incentives, and the numbers prove us right. Extensive research conducted by Bain & Company compared founder-led firms with the rest of the S&P 500 and discovered that the former group outperformed the latter nearly threefold between 1990 and 2014. Similarly, using its proprietary database of 1,000+ publicly listed family or founder-owned businesses, Credit Suisse found that between 2006 and 2020, this universe outperformed non-family-owned companies by an annual average of 370 basis points. As a side note, although the latter study found that those with the largest family ownership stakes (over 70%) achieved the highest returns, researchers do not believe that a linear relationship between the two variables can be identified. This suggests that the simple notion of family involvement appears to be the decisive factor in the outperformance of these businesses.

We can find a clear underlying distinction in how these companies allocate capital, which is essential for long-term shareholder value creation. Multiple studies have shown that if the founder or the founding family is involved, substantially more money is spent on both intangible assets and traditional capital expenditures. Note that the difference seems most staggering in the R&D category, which we think can partly be explained by the accounting treatment of these expenditures. As a reminder, research costs (along with marketing dollars) get directly expensed instead of capitalized and amortized over time (like investments in physical infrastructure), a problem the EVA framework rightfully remedies. Outside management teams are less inclined to report lower profits (even temporarily) despite the risk of underinvesting and eroding the moat. Additionally, it is no wonder that founder-involved businesses tend to have ~30% more patents than their peers, which is evidence of their propensity for taking calculated risks to foster innovation.

We believe that an owner’s mindset is not only evident in the capital allocation policy of these companies, but it also infuses them with a profound sense of purpose and drive, prioritizing sensible risk-taking and a culture of personal responsibility. As opposed to a typical public company focusing on meeting quarterly earnings guidance, a founding family’s personal net worth is tied to the business, leading to a virtuous cycle of long-term value creation. A hired CEO expecting to spend just a few years at the helm is unlikely to act in the same way as an owner-manager with an oftentimes multi-generational timescale.

The quantitative evidence certainly indicates that using founder involvement as a screening criterion has its merits as a strategy. Rob Vinall, a fund manager who openly prioritizes this aspect, states: “I invest almost exclusively in companies with active and engaged owners. Very occasionally, you find managers who think and act like owners even if no owner is present, but this is the exception rather than the rule. If a restaurant has an absentee owner, over time the service quality will slip and the waiters will have their hand in the till. With large companies, it is no different.” That being said, our primary focus in EVA Monster screening remains shareholder value creation. However, we had the impression that in our investable universe, family involvement might be higher than average. After compiling the relevant data, we discovered that every second EVA Monster in our coverage meets the criteria of family ownership with a 10%+ stake and/or is led by an actively engaged founder. This ration is at least two times higher than among members of the S&P 500 index. While it is difficult to ascertain whether there is merely a correlation or even causality between shareholder value creation and family involvement, this revelation nevertheless astonished us.

Investing in founder-led firms doesn’t guarantee success. However, the overarching idea is that, all else being equal, founders tend to exhibit higher levels of determination, discipline, resourcefulness, and self-accountability, translating to durable and oftentimes more dynamic EVA growth over the long run. Our view is unchanged in the sense that we look for the combination of a strong secular growth theme and great business strengths first and only then judge management quality or founder involvement, not the other way around. As long as there is a CEO who is a good capital allocator and business operator at the same time, their ownership background is rather irrelevant. This is a rare breed indeed, even though excellent managers such as Microsoft’s Satya Nadella are here to remind us that they do exist.

If you found this article helpful, be sure to check out our Blog for more insights and tips for your investment journey.

The EVA Monster Series: How to Fuel a Perpetual Growth Engine

With this series, we’d like to give you some perspective on the companies in our distinguished EVA Monster universe. This rare breed of quality-growth stocks is worthy of your attention, and getting to know these businesses may pay off handsomely down the road.

As a quick recap, EVA Monsters have three things in common:

  • They earn high returns on the capital they employ.
  • They have growth opportunities that allow them to reinvest most of their cash flows at high rates of return.
  • They have a sustainable competitive advantage (that Warren Buffett calls “moat”), which prevents their competitors from taking away their extraordinary profitability.

These characteristics tend to result in a strong (double-digit) fundamental return potential, meaning that no valuation tailwind is necessary to get great investment results with EVA Monsters. (These case studies explain this pretty well.)

As Charlie Munger said:

“Over the long term, it’s hard for a stock to earn a much better return that the business which underlies it earns. If the business earns 6 percent on capital over 40 years and you hold it for that 40 years, you’re not going to make much different than a 6 percent return – even if you originally buy it at a huge discount. Conversely, if a business earns 18 percent on capital over 20 or 30 years, even if you pay an expensive looking price, you’ll end up with one hell of a result.”

We also shared the math proof of why buying EVA Monster stocks at a fairish valuation makes perfect sense for long-term investors. (Look for the “math example” in this post to alleviate your doubts.)

To round off the short introduction, we (1) try to avoid overpaying for EVA Monsters, (2) closely monitor the fundamental performance and management’s capital allocation decisions throughout our holding period, and (3) hold our positions as long as the underlying investment thesis remains intact, ideally for decades, to let compounding do the heavy lifting.

Without further ado, numbers clearly prove that Constellation Software (CNSWF) is a genuine EVA Monster and a truly unique vehicle, so it is worthy of your close attention. It is remarkable how this serial acquirer built an immensely durable (shall we say perpetual) growth engine.

Constellation Software Inc. acquires, manages, and builds vertical market software (“VMS”) businesses. These entities are dedicated to delivering mission-critical software solutions tailored to the requirements of their clientele within specific industries, catering to both the public and private sectors. Constellation’s extensive portfolio comprises hundreds of companies, spanning diverse sectors such as communications, agriculture, marine applications, utilities, credit unions, beverage distribution, and hospitality. Constellation Software Inc. was incorporated in 1995 and is headquartered in Toronto, Canada.

Mark Leonard, the founder and visionary behind Constellation Software, has been serving as CEO since the company’s inception in 1995, quietly shaping a unique success story. Despite his status as one of the lowest-profile billionaires in the business world, Leonard’s impact and capital allocation skills cannot be emphasized enough. His journey began with a decade-long stint in venture capital, during which he recognized the untapped potential of small VMS firms. This realization laid the foundation for his distinctive approach of building a growth engine around these underappreciated companies.

Constellation operates across a diverse spectrum of over a hundred distinct verticals, encompassing a portfolio that spans several hundred companies. Owing to this diversified corporate framework, no individual business unit or segment holds material significance for the organization.

Maintenance and other recurring revenue (71% of fiscal 2022 sales) primarily consist of fees from customer support on software products post-delivery and include recurring fees earned through Software-as-a-Service products. Professional service revenue (21%) comes from fees charged for implementation services, custom programming, product training, and consulting.

We believe the secret sauce in Constellation’s competitive edge lies in the culture that characterizes its acquisition approach. It aims to be a perpetual owner of the acquired companies, thereby distinguishing the business from conventional private equity firms whose primary focus is the subsequent resale of their acquired assets at a premium in the future.

Notably, the firm acquires over 100 companies each year (averaging one every other business day). This pace is only possible in a decentralized decision-making framework, which also includes the critical function of capital allocation. Constellation’s corporate headquarters grants significant autonomy to subsidiary management levels, empowering them with the authority to evaluate potential acquisition targets and make informed decisions based on their assessments.

We believe another pillar of Constellation’s moat lies in the characteristics of its portfolio members. Essentially, it’s a conglomerate composed of an army of small but moaty businesses, each characterized by high switching costs. In essence, VMS companies provide highly customized solutions to meet the needs of a specific segment.

Although we do not favor serial acquirers in general (as this feature seldom aligns with consistent shareholder value creation), we hold the conviction that Constellation’s attributes justify the designation of a wide-moat enterprise.

Source: ISS EVA, The FALCON Method

As for the future, it is worth noting that the collective organic growth rates exhibited within Constellation’s portfolio of companies have been rather modest, yielding a low-to-mid-single-digit annualized CAGR over recent years. Consequently, Constellation’s growth engine can be best understood by the principle that a firm’s long-term annualized earnings growth rate converges to its reinvestment rate times the return on its incremental invested capital. Assuming that Constellation can continue allocating 80% of its internally generated cash (NOPAT) each year at 20%+ ROC levels, we arrive at a strong double-digit inorganic revenue and earnings growth potential.

At its core, this firm can be characterized as a capital-light compounder because the VMS businesses under its umbrella require very little reinvestment. Then, recurring cash flows generated by the VMS firms are harnessed to fuel a relentless acquisition engine, resulting in consistently stellar ROC levels in the 25-30% range.

Turning to shareholder distributions, Constellation pays a tiny, negligible regular dividend. In 2019, shareholders received a sizable, ~$18 per share special dividend due to the lack of attractive redeployment opportunities. Constellation has garnered a unique shareholder base that would prefer Leonard to reinvest this money instead of distributing it. Therefore, we find it unlikely that another special payout will take place in the foreseeable future, and even the ordinary dividend could be sacrificed if a better use of cash presents itself.

Looking at the stock’s valuation, Constellation’s shares have always appeared pricey on the surface. Regardless, its EVA growth over the past 5-10 years has managed to surpass even the market’s rosy expectations. Please see below the valuation metrics of the EVA framework that remedy accounting distortions to give us a clearer picture on where the stock stands in a historical context.

(Curious why we don’t use the most popular multiples? Find out here!)

The “fair” valuation range in the future hinges on the firm’s reinvestment efficiency, and as we see potential downside risks on the growth front, we have employed more conservative assumptions in our model. Nevertheless, the market-relative valuation seems unattractive at the moment with a NOPAT yield of 2.8%. Waiting for the valuation component to become at least neutral to the total return formula seems a reasonable approach at this point.

Overall, the time to get excited is not now. The “Key Data” table and the 5-year total return potential chart speak for themselves.

Source: ISS EVA, The FALCON Method

The FALCON Method can identify much better opportunities in the current market, so we are passing up on Constellation for now.

The verdict

The most obvious risk that comes to mind is that Constellation may have reached a point where it is too large to sustain its historical growth levels. The company will have to allocate as much cash in the upcoming five years as it had in the last two decades, and this raises several questions.

Furthermore, Mark Leonard’s willingness to go outside Constellation’s core circle of competence when seeking alternative options to deploy capital brings an elevated level of uncertainty. As a true value investor at heart, he warned investors that any non-VMS deal is likely to be a highly contrarian, “eyebrow-raising” type of transaction.

While challenges like the level of key personnel risk involved in this thesis do pose threats, we would be more than happy to own this business at the right price. The collection of moaty VMS businesses, paired with the head office’s corporate culture and approach to capital allocation makes us want to be an owner of this company. As for position sizing, we would be comfortable with a 2-3% exposure.

The company ranked 28th of our 60 EVA Monsters at the time of writing, based on its 5-year total return potential. (Businesses from 12 countries are represented on our EVA Monster list.)

It is safe to say that there are far more attractive EVA Monster stocks to buy in the current market, with all the highest-ranking ten boasting total return potentials above 12% over our modeled 5-year timeframe. (You can always find the monthly Top 10 in the FALCON Method Newsletter along with our entry price recommendations.)

Want to learn more about our ranking methodology? Start with this blog post!

Hitting the Sweet Spot

“The biggest mistakes I’ve made by far are mistakes of omission and not commission.” (Warren Buffett)

This blog post is dedicated to providing a behind-the-scenes look at how subjective considerations can influence the compilation of the monthly Top 10 for the newsletter, with a particular focus on our EVA Monster candidates. While the backbone of the underlying process will always be the quantitative ranking of our investable universe constituents based on their total return potentials, we argue that a more nuanced approach produces a better outcome. This, in fact, reflects the thought process behind how our analysts manage their own money, which has to be consistent with the newsletter, as this is a pillar of our integrity.

The problem with a purely quantitative ranking is that a mere total return potential figure does not fully reflect the range of possible outcomes. As a quick recap, a good rule of thumb is that we expect our typical EVA Monster to deliver an annualized fundamental return of 10-15%, comprising the firm’s EVA growth potential, share buybacks, and dividend yield. Since we derive our total return estimates by incorporating the impact of valuation, it’s unsurprising that when the total return potential significantly exceeds 10-15%, betting on a valuation rebound will likely play a pronounced role for an investment candidate.

A common theme in those situations is a rather pessimistic market perception, requiring a case-by-case evaluation with a contrarian mindset. “The best thing that happens to us is when a great company gets into temporary trouble. We want to buy them when they’re on the operating table.” The intent from this classic Buffett adage is easier said than done, as these stocks often turn out to be difficult to hold amid periods of turbulence. We reckon that when a company of EVA Monster caliber (head and shoulders above the typical S&P 500 member in quality and growth terms) gets into a dire situation, there is a good chance it will recover, much like an elite athlete having better odds on the operating table compared to a chain-smoker. Suppose an EVA Monster trades with close to zero or a negative Future Growth Reliance ratio (implying that its EVA could stagnate or shrink from the current level). In that case, it is usually a “heads I win, tails I don’t lose much” scenario. Sometimes, the market will be right, and the competitive position may have suffered damage beyond repair, serving as a bitter reminder that even though probability is on our side, this does not mean certainty. While these investment situations could offer favorable risk-reward ratios, we must also acknowledge that not all of us have the same tolerance for bearing the inherent volatility that almost always accompanies such cases.

Let’s now consider the concept of “hitting the sweet spot”. We refer to a select group of companies as “crème de la crème,” highlighting their superiority even within our elite EVA Monster universe. The common thread among them is the combination of an unassailable competitive position, exceptional reinvestment opportunities, and, more often than not, a high degree of revenue stream diversification. Microsoft, Amazon, Alphabet, LVMH, L’Oréal, and Hermès serve as prime examples of this class, although it’s important to note that this labeling represents more of a spectrum than a clear-cut categorization.

Occasionally, some of these top-tier companies come close to reaching the upper echelons of our coverage in terms of their respective total return potentials, albeit this isn’t sufficient to qualify them for the Top 10 on a quantitative basis. While our sample size is somewhat limited, we have numerous examples where companies like Microsoft, Hermès, or LVMH briefly traded at levels offering double-digit total return potentials, only to swiftly reverse their share price trajectory and perform remarkably well in subsequent periods. Hindsight is 20/20, but we argue that seizing such opportunities and including these juggernauts in the FALCON Portfolio would have been the right decision. Quoting Buffett again: “The biggest mistakes I’ve made by far are mistakes of omission and not commission. I mean, it’s the things I knew enough to do. They were within my circle of competence, and I was sucking my thumb… Those are the ones that hurt.” In these specific cases, the mistake of omission was caused by the intention to avoid compromising on the prospective return, thereby missing out on rare opportunities to become an owner of these world-class businesses.

When crunching the numbers, we must draw the line of “enough” for the total return potential somewhere, so we’ve set the goal to achieve a comfortable double-digit annualized investment return on a portfolio level. Generally, our standard approach is to pull the trigger midway between our “accumulation” and “full position” price thresholds. In practice, this means including a stock in the FALCON Portfolio when our modeled total return potential hits ~18%. This serves as a built-in margin of safety, as even if we are not entirely correct, achieving the targeted 12% total return still seems within reach.

However, there is an important distinction: the more confident we are in our modeling and the narrower the range of outcomes, the lower margin of safety should be demanded in total return terms. We argue that it is worthwhile to consider building a position in the top-notch companies even if their total return potentials “only” reach 12%, reflecting our stronger conviction that they can deliver on their modeled EVA growth trajectory. For these EVA Monsters, we would contemplate subjectively catapulting their stock into the newsletter’s Top 10, possibly coupled with inclusion in our FALCON Portfolio if they are not already members. As luck would have it, a subsequent collapse in share price can happen anytime, so buckle up for that as well. Taking advantage of those situations is the straightest path to long-term wealth building.

One thing is for sure: no matter how outstanding a business may be, its stock can always be too expensive, so we are not willing to compromise beyond a certain point. Therefore, if our model shows a single-digit total return potential, a company will never be subjectively promoted to the Top 10, let alone become a Top Pick. In such cases, we have high conviction that the valuation component could act as a headwind over the long term, likely leading to subpar investment returns. While we might be wrong at times, it is worth keeping the good old process-outcome matrix in mind to systematically judge the results of our decision-making framework. Now let’s see what the FALCON spots this time!

Where Can I Send
Your Guide?
Enter your name and email address below to get instant access.
Send Me The Guide
You will only get top-notch content from me.
close-link
Where Can I Send
Your Free Course?
Enter your name and email address below to get instant access.
Send Me The Course!
You will only get top-notch content from me.
close-link
You Can Watch The Replay Instantly...
Enter your name and email address below to get instant access.
You will only get top-notch content from us.
close-link
Upgrade your stock investing process...
Enter your name and email address below to get instant access.
You will only get top-notch content from us.
close-link